47
DAFTAR PUSTAKA
1. Fauci AS and Lane HC . Human Immunodeficiency Virus disease: AIDS and
related disorders. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser
SL, Jameson JL (eds). Harrison’s Principles of Internal Medicine Volume 1.
17th edition. New York: Mc Graw Hill Companies, pp. 1076-98.2008
2. United Nations Programme on HIV/AIDS (2012). Global report: UNAIDS
report on the Global AIDS epidemic 2012.
3. U.S. Agency for International Development . HIV/AIDS Health Profile.2010
4. Direktorat Jenderal Pemberantasan Penyakit Menular dan Penyehatan
Lingkungan, Departemen Kesehatan RI. Pedoman nasional perawatan,
dukungan dan pengobatan bagi ODHA. Jakarta: Dep Kes RI; 2013.
5. Dinkes Provisi Sumatera Utara . Bidang Penanggulangan Penyakit
Menular dan Penyehatan Lingkungan (P2MPL). Kasus HIV/AIDS 2012;2013
6. Mehta AK, Anderson AM ,Wang YF, Jing Q, Easley K, Nguyen ML.
HIV-associated histoplasmosis in a nonendemic area of the United States
during the HAART era: role of migration from endemic areas and lack of
antiretroviral therapy. J Int Assoc Physicians AIDS Care (Chic). 2010
Sep-Oct;9(5):296-300.
7. Kementerian Kesehatan RI . Direktorat Jenderal Pengendalian Penyakit
dan Penyehatan Lingkungan (Ditjen P2PL). Pedoman Nasional Tatalaksana
Klinis Infeksi HIV dan Terapi Antiretroviral pada Orang Dewasa dan
Remaja.2011
8. World Health Organization .Antiretroviral therapyforHIV infection in
adultsand adolescents: Recommendations for a publichealth
48
9. Lundgren JD, Mocroft A. Anemia and survival in human 8.
immunodeficiency virus. Clin Infect Dis 2003; 37 (Suppl 4): S297-303.
10. Curkendall SM, Richardson JT, Emons MF, Fisher AE,Everhard F. Incidence
of anaemia among HIV-infected patients treated with highly active
antiretroviral therapy. HIV Med 2007; 8 : 483-90.
11. Weinkove R, Rangarajan S, van der Walt J, Kulasegaram R. 13.
Zidovudine-induced pure red cell aplasia presenting after 4 years of therapy. AIDS
2005; 19 : 2046-7.
12. Dipti Agarwal, Jaya Chakravarty, Lavina Chaube, Madhukar Rai, Nisha Rani
Agrawal & Shyam Sundar,High incidence of zidovudine induced anaemia
in HIV infected patients in eastern India,Indian J Med Res 132, October
2010, pp 386-389
13. Surendra K Sharma, Zidovudine-induced anaemia in HIV/AIDS, Indian J
Med Res 132, October 2010; pp 359-361
14. Hassan A, Babadoko AA, Mamman AI, Ahmed SA. 12. Zidovudine induced
pure red cell aplasia: a case report. Niger J Med 2009; 18 : 332-3.
15. Fauci AS , HIV and AIDS: 20 years of science. Nature Medicine,2003 ;9(7):
839-43.
16. Levy JA , HIV pathogenesis: 25 years of progress and persistent
challenges. AIDS, 2009;23: 147-60
17. Montagnier L . 25 years after HIV discovery: prospects for cure and
vaccine. Nobel Lecture, World Foundation for AIDS Research and
Prevention, UNESCO.2008
18. U.S. Government , U.S. Government Source for HIV/AIDS Medical Practice
Guidelines, Clinical Trials and Other Research Information. The 7th
49
19. World Health Organization ,WHO Case Definitions of HIV and Revised
Clinical Staging and Immunological Clasification of HIV-related disease in
Adult and Children,2007b
20. Nasronudin , HIV & AIDS: Pendekatan Biologi Molekuler, Klinis dan Sosial.
Surabaya: Airlangga University Press.2007
21. World Health Organization , Laboratory Guidelines for Enumerating CD4 T
Lymphocytes in the Context of HIV/AIDS.2007a
22. Wormster GP, The epidemiologi of HIV and AIDS in AIDS and other
manifestation of HIV infection. New York:Medical College Villaha;2005.
23. World Health Organization, Regional Office for South-East Asia.
Management of HIV infection and antiretroviral therapy in adults and
adolescents. A Clinical Manual.2007.
24. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM,
Katzenstein DA, et al.Antiretroviral therapy for HIV infection in 1996.
Recommendations of aninternational panel. International AIDS
Society-USA. JAMA. 1996;276(2):46-54.
25. Gazzard B. What we know so far. AIDS. 1996;10 ( Suppl 1):S3-7.
26. Kementerian Kesehatan RI . Direktorat Jenderal Pengendalian Penyakit
dan Penyehatan Lingkungan (Ditjen P2PL). Laporan perkembangan
HIV/AIDS triwulan III tahun2012.
27. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al.
Atherogenic dyslipidemia in HIV-infected individuals treated with
protease inhibitors. The Swiss HIV Cohort Study. Circulation.
1999;100(7):700-5.
28. Zhu J and Paul WE . CD4 T cells: fates, functions, and faults. Blood, 112:
50
29. Raoul Moh, Christine Danel.Haematological changes in adults receiving a
zidovudine-containing HAART regimen in combination with cotrimoxazole
in Cote d'Ivoire,Antiviral Therapy 10:615–624.2002
30. Surendra K. Sharma,Zidovudine-induced anaemia in HIV/AIDS.Indian J
Med Res 132, October 2010, pp 359-361
31. Moyle G. Anaemia in persons with HIV infection : prognostic marker and
contributor to morbidity. AIDS Reviews.2002;4:13-20
32. Richman DD,Fischl MA,Grieco MH, Gottlieb MS, Volberding PA, Laskin OL,
Leedom JM, Groopman JE, Mildvan D & Hirch MS. The toxicity of
azidothymidine (AZT) in thr treatment of patients with AIDS and AIDS
related complex. A double-blind placebo-controlled trial. New England
Journal of Medicine 1987;317:192-197
33. SE Huffam, P Srasuebkul ,Prior antiretroviral therapy experience protects
against
zidovudine-related anaemia ,on behalf of The TREAT Asia
HIVObservational Database (TAHOD),HIV Medicine (2007), 8, 465–471.
34. S. Takuva, G. Louwagie,K. Zuma, andV.Okello, “Durability of first line
antiretroviral therapy: reasons and predictive factors for modifications in
a Swaziland Cohort,” Journal of Antivirals and Antiretrovirals, vol. 4, no. 1,
pp. 14–20, 2012.
35. Kavindhran Velen, James J. Lewis, Comparison of Tenofovir, Zidovudine,
or Stavudine as Part of First-Line Antiretroviral Therapy in a Resource-
Limited-Setting: A Cohort Study;PLOS ONE, www.plosone.org 1 May
2013, Volume 8, Issue 5.
